Outcomes in patients with chronic lymphocytic leukemia and TP53 aberration who received first-line ibrutinib: a nationwide registry study from the Italian Medicines Agency

In this analysis we describe the effectiveness of first-line ibrutinib in 747 patients with chronic lymphocytic leukemia (CLL) and TP53 aberrations in a nationwide study with a 100% capture of patients who received the study drug. Median age was 71 years (range 32–95). An estimated treatment persist...

Descripción completa

Detalles Bibliográficos
Autores principales: Rigolin, Gian Matteo, Olimpieri, Pier Paolo, Summa, Valentina, Celant, Simone, Scarfò, Lydia, Tognolo, Lucia, Ballardini, Maria Pia, Urso, Antonio, Sessa, Mariarosaria, Gambara, Silvia, Cura, Francesca, Fortini, Monica, Ghia, Paolo, Cuneo, Antonio, Russo, Pierluigi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10307816/
https://www.ncbi.nlm.nih.gov/pubmed/37380630
http://dx.doi.org/10.1038/s41408-023-00865-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10307816/
https://www.ncbi.nlm.nih.gov/pubmed/37380630
http://dx.doi.org/10.1038/s41408-023-00865-z

Ejemplares similares